Press Releases Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Real-time Estimate Cboe BZX Other stock markets 08:51:31 10/05/2024 pm IST			5-day change	1st Jan Change
7.185 ^USD	+0.21%		-4.80%	+224.55%

01/04	ADRs End Higher; Connect Biopharma Climbs 26%	DJ
28/03	ADRs End Lower; NuCana Slides 15%	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	30/04	AQ
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK	28/03	AQ
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	26/03	AQ
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	14/03	AQ
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)	11/03	AQ
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023	29/02	AQ
Mesoblast Financial Results and Corporate Update Webcast	26/02	AQ
MESOBLAST - UNITED STATES FOOD & DRUG ADMINISTRATION GRANTS MESOBLAST ORPHAN-DRUG DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	15/02	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	15/02	AQ
MESOBLAST LIMITED - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED DECEMBER 31, 2023	31/01	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023	31/01	AQ
MESOBLAST - UNITED STATES FOOD AND DRUG ADMINISTRATION GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	19/01	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	19/01	AQ
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease	27/11	AQ
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD	22/11	AQ
MESOBLAST - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED SEPTEMBER 30, 2023	31/23/31	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023	31/23/31	AQ
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee	26/23/26	AQ
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval	21/23/21	AQ
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023	31/23/31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Press Releases

Filters